Crexont (IPX203) vs Levodopa/carbidopa (ND0612)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Parkinson's Disease
Shared mechanism: dopamine precursor · full Parkinson's Disease pipeline
Crexont (IPX203)
Marketed by Amneal Pharmaceuticals and partners
NCT03670953 · Phase 3 · completed
The study was randomized, quadruple-blind, double-dummy, and active-controlled, with 506 participants entering the randomized maintenance period and 495 contributing primary-endpoint data. The clinical primary endpoint was met: IPX203 produced a significantly greater improvement in daily “good on” time than immediate-release carbidopa-levodopa (p=0.0194).
Next expected readout: February 2027 · NCT07138560 (registry estimate)
Reported efficacy
Mean Change From Baseline in "Good on" Time Per Day at Week 20/Early Termination (ET) (Baseline (Week 7) and Week 20/ET): Mean Change From Baseline in "Good on" Time Per Day at Week 20/Early Termination (ET) (Baseline (Week 7) and Week 20/ET): IPX203 - Double-Blind Maintenance — Baseline (Week 7): 11.67 hours/day (Standard Deviation 2.943); Change at Week 20/ET: -0.39 hours/day (Standard Deviation 2.706) vs IR CD-LD - Double -Blind Maintenance — Baseline (Week 7): 11.72 hours/day (Standard Deviation 2.759); Change at Week 20/ET: -0.97 hours/day (Standard Deviation 3.081) (met)
Result source: NCT03670953
Levodopa/carbidopa (ND0612) · Onerji
Marketed by NeuroDerm Ltd.
NCT02577523 · Phase 2 · completed
Participants were randomized to two ND0612 regimens, but the study was only single-blinded for outcome assessors, had no placebo or active-control arm, and was small with 19 participants per group. The clinical primary endpoint was daily OFF time; although the 24-hour regimen showed a numerically greater reduction, statistical significance for the comparison was not reported, so the result is unclear.
Reported efficacy
Change in Daily "OFF" Time (Baseline to Day 28): Change in Daily "OFF" Time (Baseline to Day 28): ND0612 Regimen 1 - 24-hr Infusion -2.8 Hours (95% CI -4.6--0.9) vs ND0612 Regimen 2 - 14-hr Infusion -1.3 Hours (95% CI -3.1-0.5) (unclear)
Result source: NCT02577523
Results for Parkinson's Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Crexont (IPX203) | Levodopa/carbidopa (ND0612) |
|---|---|---|
| OFF time, change | —Not reported | -2.1 vs -1.4−0.7 vs placeboNCT01883505 |
| ON time without troublesome dyskinesia, change | —Not reported | —Trial running · NCT04006210 |
| UPDRS Part III, change | —Not reported | —Trial running · NCT04006210 |
| MDS-UPDRS Part II, change | —Not reported | —Trial running · NCT04006210 |
OFF time, change
- Crexont (IPX203)
- —Not reported
- Levodopa/carbidopa (ND0612)
- -2.1 vs -1.4−0.7 vs placeboNCT01883505
ON time without troublesome dyskinesia, change
- Crexont (IPX203)
- —Not reported
- Levodopa/carbidopa (ND0612)
- —Trial running · NCT04006210
UPDRS Part III, change
- Crexont (IPX203)
- —Not reported
- Levodopa/carbidopa (ND0612)
- —Trial running · NCT04006210
MDS-UPDRS Part II, change
- Crexont (IPX203)
- —Not reported
- Levodopa/carbidopa (ND0612)
- —Trial running · NCT04006210
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Crexont (IPX203): 2 of 4 rows · Levodopa/carbidopa (ND0612): 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Crexont (IPX203) | Levodopa/carbidopa (ND0612) |
|---|---|---|
| Dropout rate | —IPX203 - Dose Conversion NCT03670953 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 show 1 more result—IPX203 - Double-Blind Maintenance NCT03670953 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 | —24-hr Infusiona NCT02577523 · Phase 2 show 4 more results—14-hr Infusion NCT02577523 · Phase 2 0%Period 1. ND0612 NCT01883505 · Phase 2 · registry result, not featured evidence —Period 2. ND0612 NCT01883505 · Phase 2 · registry result, not featured evidence —Period 2. ND0612 + Entacapone NCT01883505 · Phase 2 · registry result, not featured evidence · combination |
| Discontinued due to AEs | —IPX203 - Dose Conversion NCT03670953 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 show 1 more result—IPX203 - Double-Blind Maintenance NCT03670953 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 | —24-hr Infusiona NCT02577523 · Phase 2 show 4 more results—14-hr Infusion NCT02577523 · Phase 2 —Period 1. ND0612 NCT01883505 · Phase 2 · registry result, not featured evidence —Period 2. ND0612 NCT01883505 · Phase 2 · registry result, not featured evidence —Period 2. ND0612 + Entacapone NCT01883505 · Phase 2 · registry result, not featured evidence · combination |
| Serious AEs | 2%IPX203 - Dose Conversion NCT03670953 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 show 1 more result3.1%IPX203 - Double-Blind Maintenance NCT03670953 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 | 10.5%24-hr Infusiona NCT02577523 · Phase 2 show 4 more results10.5%14-hr Infusion NCT02577523 · Phase 2 5.3%Period 1. ND0612 NCT01883505 · Phase 2 · registry result, not featured evidence 0%Period 2. ND0612 NCT01883505 · Phase 2 · registry result, not featured evidence 0%Period 2. ND0612 + Entacapone NCT01883505 · Phase 2 · registry result, not featured evidence · combination |
| Most frequent reported AEs | dyskinesia 6.8% nausea 4.9% dry mouth 4.2% NCT03670953 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 show 1 more resultnausea 4.3% anxiety 2.7% dizziness 2.3% NCT03670953 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 | 24-hr Infusiona infusion site nodule 57.9% infusion site erythema 26.3% infusion site bruising 21.1% NCT02577523 · Phase 2 show 4 more results14-hr Infusion infusion site nodule 36.8% infusion site bruising 15.8% infusion site haemorrhage 15.8% NCT02577523 · Phase 2 fatigue 10.5% (placebo 0%) headache 10.5% (placebo 9.1%) abdominal pain lower 5.3% (placebo 0%) NCT01883505 · Phase 2 · registry result, not featured evidence blood creatinine abnormal 12.5% (placebo 0%) dental caries 12.5% (placebo 0%) diarrhoea 12.5% (placebo 0%) NCT01883505 · Phase 2 · registry result, not featured evidence back pain 12.5% (placebo 0%) pain in extremity 12.5% (placebo 9.1%) abdominal pain lower 0% (placebo 0%) NCT01883505 · Phase 2 · registry result, not featured evidence · combination |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Crexont (IPX203)
Levodopa/carbidopa (ND0612)
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
+ 1 further endpoint in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Crexont (IPX203)'s landscape · Levodopa/carbidopa (ND0612)'s landscape